Enox Biopharma, Inc. Will Be Granted its Foundation Patent

VANCOUVER, British Columbia, Aug. 22, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, today announced that it has received a notice of allowance from the US Patent Office that its patent application entitled "Antimicrobial Gas-Releasing Ear Drainage Tubes" has been approved and a patent will granted.

This patent was the first applied for by Enox and is the foundation patent of the company. The notice of allowance for this patent underscores the novelty of Enox's technology which utilizes nitric oxide gas embedded into polymers as an antimicrobial to prevent hospital acquired infections. Nitric oxide is well recognized as an ideal antimicrobial agent that is highly effective yet free from the drug resistance issues that have resulted from excessive antibiotic use. Additional patent applications, which are under review in the United States and in countries around the world, expand the use of antimicrobial gas releasing technology to virtually any polymer-based medical device.

"This is a very significant patent for Enox. Not only does it solidify our intellectual property portfolio, it is rigorous external validation of our technology being the first of its kind. With our foundation patent issued, the probability of our other intellectual property applications being successful is increased," stated Enox CEO, John Rewcastle, Ph.D. "Nitric oxide emitting medical devices have a unique potential to reduce hospital acquired infections which are a global problem costing tens of billions of dollars annually. The issuance of this patent further ensures Enox is the only company that can create such devices."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D., CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
[email protected]
www.enoxbiopharma.com

SOURCE Enox Biopharma, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED